Clinical Trials on Advanced Melanoma in United Kingdom

Total 4605 results

California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)

Metastatic Melanoma

United States, Spain, Germany, United Kingdom, France, Hungary, Italy, Switzerland
BioVex Limited

Completed

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Melanoma

United States, United Kingdom
Hoffmann-La Roche

Completed

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Malignant Melanoma, Neoplasms

United States, South Africa, Croatia, Brazil, Egypt
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
Momentum Data
Pfizer

Completed

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Vitiligo | Melanoma (Skin) | Actinic Keratoses | Basal Cell Carcinoma | Squamous Cell Carcinoma | Nonmelanoma Skin Cancer

United Kingdom
Providence Health & Services
Merck Sharp & Dohme LLC; Eisai Inc.

Recruiting

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Melanoma, Uveal

United States
University of Colorado, Denver
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Malignant Melanoma

United States
Providence Health & Services
Prometheus Laboratories

Active, not recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. (SBRT/IL-2)

Metastatic Melanoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Radiation and Combination Immunotherapy for Melanoma

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Metastatic Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
OHSU Knight Cancer Institute

Completed

Vascular Response to Brachytherapy Using Functional OCT

Uveal Melanoma

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Completed

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Malignant Melanoma

United States
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Celgene
Prologue Research International

Completed

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Malignant Melanoma

United States
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics...

Completed

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Milton S. Hershey Medical Center

Completed

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Malignant Melanoma

United States
University of Arizona

Terminated

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

Malignant Melanoma

United States
Western Regional Medical Center

Terminated

Interleukin-2 in Metastatic Melanoma

Melanoma Metastatic

United States
New England Retina Associates

Completed

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Choroidal Melanoma

United States
New England Retina Associates
Genentech, Inc.

Completed

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Choroidal Melanoma

United States
University of California, Davis

Completed

Comparison of Video-Based Versus Written Patient Education on Melanoma

Melanoma | Malignant Melanoma

United States
University of Massachusetts, Worcester

Completed

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

Metastatic Melanoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye

Intraocular Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Melanoma (Skin)

United States
New England Retina Associates

Completed

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

Choroidal Melanoma

United States
M.D. Anderson Cancer Center
Aventis Pharmaceuticals

Completed

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Metastatic Melanoma

United States
Molecular Insight Pharmaceuticals, Inc.

Terminated

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

Metastatic Melanoma

United States
UNC Lineberger Comprehensive Cancer Center
Amgen

Completed

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Melanoma | Melanoma (Skin) | Melanoma Stage Iv | Melanoma Stage Iii | Cutaneous Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
TransMolecular

Terminated

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

Melanoma | Metastatic Melanoma | Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Recurrent Melanoma | Stage IV Melanoma | Uveal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

Canada, United States
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Syntrix Biosystems, Inc.
M.D. Anderson Cancer Center; National Cancer Institute (NCI); Massachusetts General... and other collaborators

Recruiting

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Melanoma Stage IV | Melanoma Stage III

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Aura Biosciences

Recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma | Indeterminate Lesions

United States, Australia, United Kingdom
University of Kansas Medical Center

Completed

Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma

Malignant Melanoma

United States

Clinical Trials on Advanced Melanoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations